… neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and others.
Glucagon-like peptide 1 (GLP-1) … Several clinical trials have been conducted, testing GLP-1 …

… frequent neurodegenerative disorders. These findings have led to numerous studies in
preclinical models of neurodegenerative disorders targeting insulin/IGF-1 and GLP-1 signaling …

… Furthermore, GLP-1R stimulating drugs have been … in neurodegenerative disorder
preclinical models, and hence hold promise for repurposing as a treatment for neurodegenerative …

… A different progressive neurodegenerative disorder that may be treated with GLP-1 mimetics
is amyotrophic lateral sclerosis (ALS). The dominant symptom is increased motor neuron …

… , as well as between T2DM and neurodegenerative disorders such as AD and PD. Thus,
it is conceivable that these beneficial effects of GLP-1 receptor activation may be relevant in …

… neurodegenerative diseases. Huntington’s disease is an autosomal dominant neurodegenerative
disorder … clinically manifests as hyperkinetic movement disorder and cognitive decline. …

… of the precursor protein GLP-1(1–37) generate two GLP-1 active forms with the same
biological activity namely GLP-1 (7–37) and the amidated GLP-1 (7–36). GLP-1 is degraded by a …

… function, autophagy, synaptic strength in neurodegenerative disorders. MAPK pathway
regulates various cellular activities including synaptic plasticity and neuroinflammation. When …

… of insulin and GLP-1 signalling in the CNS, as well as the preclinical data for the use of GLP-1
analogues such as liraglutide, exenatide and lixisenatide in neurodegenerative diseases. …

… Epidemiological studies found a correlation between type 2 diabetes mellitus (T2DM) and
an increased risk of developing AD or other neurodegenerative disorders at a later stage [158]…